Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VRX
|
|||
| Former ID |
DNC000689
|
|||
| Drug Name |
GHRP-2
|
|||
| Synonyms |
Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Growth hormone deficiency [ICD-11: 5A61.3] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C45H55N9O6
|
|||
| Canonical SMILES |
CC(C(=O)NC(CC1=CC2=CC=CC=C2C=C1)C(=O)NC(C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCCN)C(=O)N)N
|
|||
| InChI |
1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
|
|||
| InChIKey |
HRNLPPBUBKMZMT-RDRUQFPZSA-N
|
|||
| CAS Number |
CAS 158861-67-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135890
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth hormone secretagogue receptor 1 (GHSR) | Target Info | Agonist | [2] |
| Phosphogluconate dehydrogenase (PGD) | Target Info | Inhibitor | [3] | |
| BioCyc | Pentose phosphate pathway | |||
| Pentose phosphate pathway (oxidative branch) | ||||
| KEGG Pathway | Pentose phosphate pathway | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Panther Pathway | Pentose phosphate pathway | |||
| Pathwhiz Pathway | Warburg Effect | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Metabolism of carbohydrates | ||||
| Pentose Phosphate Pathway | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68. | |||
| REF 3 | Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.